Correction: Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials

• Jimin Ren,
• Richard B. Dewey,
• Austin Rynders,
• Jacob Evan,
• Jeremy Evan,
• Shelia Ligozio,
• Karen S. Ho,
• Peter V. Sguigna,
• Robert Glanzman,
• Michael T. Hotchkin,
• Richard B. Dewey,
• Benjamin M. Greenberg

Affiliations

Jimin Ren

Department of Neurology, University of Texas Southwestern Medical Center

Richard B. Dewey

Department of Neurology, University of Texas Southwestern Medical Center

Austin Rynders

3Clene Nanomedicine, Inc.

Jacob Evan

3Clene Nanomedicine, Inc.

Jeremy Evan

3Clene Nanomedicine, Inc.

Shelia Ligozio

Instat Clinical Research, A Veristat Company

Karen S. Ho

3Clene Nanomedicine, Inc.

Peter V. Sguigna

Department of Neurology, University of Texas Southwestern Medical Center

Robert Glanzman

3Clene Nanomedicine, Inc.

Michael T. Hotchkin

3Clene Nanomedicine, Inc.

Richard B. Dewey

Department of Neurology, University of Texas Southwestern Medical Center

Benjamin M. Greenberg

Department of Neurology, University of Texas Southwestern Medical Center